Hemoglobin News and Research

RSS
New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

June issue of Clinic Women's HealthSource provides overview of anemia

June issue of Clinic Women's HealthSource provides overview of anemia

Masimo announces limited market release of Pronto-7 handheld hemoglobin spot-check testing device

Masimo announces limited market release of Pronto-7 handheld hemoglobin spot-check testing device

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

Ultrasound-guided diffuse optical tomography holds promise for ascertaining early-stage invasive breast cancer

Ultrasound-guided diffuse optical tomography holds promise for ascertaining early-stage invasive breast cancer

Study shows vitamin D deficiency is highly prevalent in patients with Type 2 diabetes

Study shows vitamin D deficiency is highly prevalent in patients with Type 2 diabetes

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

NHLBI funds nine research grants to determine safety and efficacy of red blood cell transfusions

"Lap Band" weight loss surgery improves physical, psychological health in extremely obese adults

"Lap Band" weight loss surgery improves physical, psychological health in extremely obese adults

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

A review of the response to oral anti-diabetes agents in patients with type 2 diabetes

A review of the response to oral anti-diabetes agents in patients with type 2 diabetes

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

New independent study demonstrates clinical accuracy of Masimo noninvasive and continuous hemoglobin monitoring

New independent study demonstrates clinical accuracy of Masimo noninvasive and continuous hemoglobin monitoring

New research evaluating substantial disease burden of PNH presented at European Hematology Association

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Hooper Holmes' Heritage Labs division receives Certificate of Registration

Hooper Holmes' Heritage Labs division receives Certificate of Registration

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

Gene variant linked to ability of Tibetans to cope with low-oxygen conditions identified

Gene variant linked to ability of Tibetans to cope with low-oxygen conditions identified

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.